Intel stock extends gains after report of possible U.S. government stake
Silo Pharma , Inc. (NASDAQ:SILO), a pharmaceutical company based in Sarasota, Florida, has been granted a patent for a new pharmacological agent aimed at preventing stress-induced affective disorders in females. The United States Patent and Trademark Office issued Patent No. US 12,239,614 on March 4, 2025, following an exclusive licensing agreement with Columbia University. The company, currently valued at $5.87 million in market capitalization, has seen its stock surge 47% year-to-date, according to InvestingPro data.
The patent, originally filed under Serial No. 17/954864, covers the development of "Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females." This new treatment represents a potential advancement in the field of mental health, specifically targeting stress-related conditions which can lead to disorders such as depression and anxiety. InvestingPro analysis shows the company maintains impressive gross profit margins of 91.9% and holds more cash than debt on its balance sheet.
The announcement of the patent grant was made public through a Form 8-K filing with the Securities and Exchange Commission (SEC) on Friday, March 7, 2025. The filing also included standard financial statements and exhibits as required by the SEC.
Silo Pharma, Inc., which trades on The Nasdaq Stock Market LLC under the ticker symbol (NASDAQ:SILO), has a history of name changes, previously known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc., reflecting the company’s evolution over time.
This development may be of particular interest to investors and stakeholders in the pharmaceutical industry, as well as to the broader medical community. It signifies Silo Pharma’s ongoing efforts in research and development within the pharmaceutical preparations sector, classified under the Standard Industrial Classification code 2834.
The information provided in this article is based solely on the press release statement from the SEC filing, and it presents the facts without any endorsement of claims. No further details regarding the implications of the patent or the potential market impact were disclosed in the filing. Investors following this development should note that Silo Pharma is currently trading below its Fair Value, according to InvestingPro analysis, with the company scheduled to report its next earnings on March 26, 2025. For comprehensive analysis and additional insights, including 8 more exclusive ProTips, visit InvestingPro.
In other recent news, Silo Pharma has reported positive preliminary results from a study on its SP-26 ketamine extended-release rods for chronic pain and fibromyalgia treatment. The study, which is in its early stages and involves small animal testing, has shown no serious side effects or discomfort, with comprehensive safety and pharmacokinetic reports expected by March 2025. Additionally, the company has filed a provisional patent application for its lead asset, SPC-15, aimed at treating stress-induced psychiatric disorders such as PTSD. This patent application, which focuses on the combinatorial targeting of specific receptors, is part of Silo Pharma’s strategy to enhance its intellectual property portfolio. In another development, the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application related to SPC-15, marking a significant milestone for the company. The approval of this patent is expected to strengthen Silo’s market position and intellectual property rights. Silo Pharma’s CEO, Eric Weisblum, has expressed optimism about these advancements, which are part of the company’s broader efforts to innovate in the areas of mental health and chronic pain management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.